Low Density Lipoprotein (LDL)

Catalogue Number: 360-30
Product Name Low Density Lipoprotein
Source Human Plasma
Catalogue Number 360-30
Formulation 0.2 micron filtered solution in phosphate buffered saline, pH 7.4 with 0.3 mM EDTA and 0.05% ProClin™ 300
Form Liquid
Purity > 95% (SDS-PAGE)
Appearance Yellow to orange liquid
Protein 5 - 8 mg/mL (Modified Lowry)
LDL Cholesterol > 500 mg/dL (Enzymatic)
Total Cholesterol > 500 mg/dL (Enzymatic)
Triglyceride Report in mg/dL (Enzymatic)
Triglyceride Ratio < 0.50
Electrophoresis One major band consistent with LDL, HDL not detected (Helena QuickGel® Cholesterol)
Related Products 360-10 - LDL Concentrate from human plasma
360-31 - High Purity Copper Oxidized LDL from human plasma
Storage 2-8°C
Recertification 6 months from date of manufacture
Infectious Disease Testing Negative or non-reactive at the donor level for anti-HIV 1 and 2, anti-HCV, HBsAg, HIV-1 (NAT), HBV (NAT), HCV (NAT), and syphilis by FDA approved methods.
Synonyms LDL, LDL-C, Beta-Lipoprotein, Concentrate, Fraction
Country of Origin United States

Lee Biosolutions is world leader in the manufacturing of human plasma lipoproteins, including native antigens and modified LDL and HDL for research and in vitro diagnostic (IVD) manufacturing uses.

Custom LDL/HDL and triglyceride ratios, technical support, bulk quantities and aliquoting available, email Info@leebio.com for more details.


Low-density lipoprotein (LDL), often deemed the “bad cholesterol”, is a lipoprotein that carries cholesterol throughout the body via blood circulation. Due to its role in dispositioning cholesterol TO tissues and organs of the body, having high levels of LDL can lead to plaque formation in the arteries, possibly increasing the risk of heart disease and stroke. (American Heart Association, 2014)

It is recommended by the National Heart, Lung, and Blood Institute to maintain a LDL cholesterol level lower than 100 mg/dL, optimally. (National Heart, Lung, and Blood Institute, 2016)


Diagnostic – Clinical calibration control

Source of antigens for developing antibodies

Cholesterol Research in regards to pharmaceutical drug development and familial hypercholesterolaemia (Varghese, 2014)

Developing new methods of LDL measurement (Nauck, Warnick, & Rifai, 2002)


LDL size has been shown to be linked to cardiovascular health. The larger the LDL particles, the greater correlation to a cardiovascular event. (Foroutan, MS, RDN, 2015)

Lowering LDL to the levels of a new-born baby has been shown to dramatically decrease the risk of heart disease. (News Medical Life Sciences, 2016)

Direct homogeneous assays rather than determining LDL-C values based on the Friedewald calculation may improve lipoprotein analyses and allow for a more accurate LDL value, especially in regards to patients suffering from hyperlipidemia (Nauck, Warnick, & Rifai, 2002).

Add to Cart
360-30-1 $ 135.00 1 mg
360-30-10 $ 575.00 10 mg
360-30-100 Inquire 100 mg